172 related articles for article (PubMed ID: 30922855)
1. Lysosomal enzyme activities as possible CSF biomarkers of synucleinopathies.
Paciotti S; Gatticchi L; Beccari T; Parnetti L
Clin Chim Acta; 2019 Aug; 495():13-24. PubMed ID: 30922855
[TBL] [Abstract][Full Text] [Related]
2. Selective loss of glucocerebrosidase activity in sporadic Parkinson's disease and dementia with Lewy bodies.
Chiasserini D; Paciotti S; Eusebi P; Persichetti E; Tasegian A; Kurzawa-Akanbi M; Chinnery PF; Morris CM; Calabresi P; Parnetti L; Beccari T
Mol Neurodegener; 2015 Mar; 10():15. PubMed ID: 25881142
[TBL] [Abstract][Full Text] [Related]
3. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.
Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D
J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146
[TBL] [Abstract][Full Text] [Related]
4. Characterization of Brain Lysosomal Activities in GBA-Related and Sporadic Parkinson's Disease and Dementia with Lewy Bodies.
Moors TE; Paciotti S; Ingrassia A; Quadri M; Breedveld G; Tasegian A; Chiasserini D; Eusebi P; Duran-Pacheco G; Kremer T; Calabresi P; Bonifati V; Parnetti L; Beccari T; van de Berg WDJ
Mol Neurobiol; 2019 Feb; 56(2):1344-1355. PubMed ID: 29948939
[TBL] [Abstract][Full Text] [Related]
5. Impaired Sphingolipid Hydrolase Activities in Dementia with Lewy Bodies and Multiple System Atrophy.
Usenko TS; Senkevich KA; Bezrukova AI; Baydakova GV; Basharova KS; Zhuravlev AS; Gracheva EV; Kudrevatykh AV; Miliukhina IV; Krasakov IV; Khublarova LA; Fursova IV; Zakharov DV; Timofeeva AA; Irishina YA; Palchikova EI; Zalutskaya NM; Emelyanov AK; Zakharova EY; Pchelina SN
Mol Neurobiol; 2022 Apr; 59(4):2277-2287. PubMed ID: 35066761
[TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal fluid β-glucocerebrosidase activity is reduced in parkinson's disease patients.
Parnetti L; Paciotti S; Eusebi P; Dardis A; Zampieri S; Chiasserini D; Tasegian A; Tambasco N; Bembi B; Calabresi P; Beccari T
Mov Disord; 2017 Oct; 32(10):1423-1431. PubMed ID: 28843015
[TBL] [Abstract][Full Text] [Related]
7. Axonal Transport of Lysosomes Is Unaffected in Glucocerebrosidase-Inhibited iPSC-Derived Forebrain Neurons.
Keefe AJ; Gabrych DR; Zhu Y; Vocadlo DJ; Silverman MA
eNeuro; 2023 Oct; 10(10):. PubMed ID: 37816595
[TBL] [Abstract][Full Text] [Related]
8. GBA1 mutations: Prospects for exosomal biomarkers in α-synuclein pathologies.
Johnson PH; Weinreb NJ; Cloyd JC; Tuite PJ; Kartha RV
Mol Genet Metab; 2020 Feb; 129(2):35-46. PubMed ID: 31761523
[TBL] [Abstract][Full Text] [Related]
9. Glucocerebrosidase dysfunction in neurodegenerative disease.
Brooker SM; Krainc D
Essays Biochem; 2021 Dec; 65(7):873-883. PubMed ID: 34528667
[TBL] [Abstract][Full Text] [Related]
10. Path mediation analysis reveals GBA impacts Lewy body disease status by increasing α-synuclein levels.
Gündner AL; Duran-Pacheco G; Zimmermann S; Ruf I; Moors T; Baumann K; Jagasia R; van de Berg WDJ; Kremer T
Neurobiol Dis; 2019 Jan; 121():205-213. PubMed ID: 30236861
[TBL] [Abstract][Full Text] [Related]
11. Lysosomal Dysfunction and α-Synuclein Aggregation in Parkinson's Disease: Diagnostic Links.
Moors T; Paciotti S; Chiasserini D; Calabresi P; Parnetti L; Beccari T; van de Berg WD
Mov Disord; 2016 Jun; 31(6):791-801. PubMed ID: 26923732
[TBL] [Abstract][Full Text] [Related]
12. Parkinson's disease: acid-glucocerebrosidase activity and alpha-synuclein clearance.
Blanz J; Saftig P
J Neurochem; 2016 Oct; 139 Suppl 1():198-215. PubMed ID: 26860955
[TBL] [Abstract][Full Text] [Related]
13. Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinson's disease.
Huebecker M; Moloney EB; van der Spoel AC; Priestman DA; Isacson O; Hallett PJ; Platt FM
Mol Neurodegener; 2019 Nov; 14(1):40. PubMed ID: 31703585
[TBL] [Abstract][Full Text] [Related]
14. Factors influencing the measurement of lysosomal enzymes activity in human cerebrospinal fluid.
Persichetti E; Chiasserini D; Parnetti L; Eusebi P; Paciotti S; De Carlo C; Codini M; Tambasco N; Rossi A; El-Agnaf OM; Calabresi P; Beccari T
PLoS One; 2014; 9(7):e101453. PubMed ID: 24983953
[TBL] [Abstract][Full Text] [Related]
15. Fibroblasts from idiopathic Parkinson's disease exhibit deficiency of lysosomal glucocerebrosidase activity associated with reduced levels of the trafficking receptor LIMP2.
Thomas R; Moloney EB; Macbain ZK; Hallett PJ; Isacson O
Mol Brain; 2021 Jan; 14(1):16. PubMed ID: 33468204
[TBL] [Abstract][Full Text] [Related]
16. Saposin C, Key Regulator in the Alpha-Synuclein Degradation Mediated by Lysosome.
Ruz C; Barrero FJ; Pelegrina J; Bandrés-Ciga S; Vives F; Duran R
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233303
[TBL] [Abstract][Full Text] [Related]
17. Changes in endolysosomal enzyme activities in cerebrospinal fluid of patients with Parkinson's disease.
van Dijk KD; Persichetti E; Chiasserini D; Eusebi P; Beccari T; Calabresi P; Berendse HW; Parnetti L; van de Berg WD
Mov Disord; 2013 Jun; 28(6):747-54. PubMed ID: 23712522
[TBL] [Abstract][Full Text] [Related]
18. Glucocerebrosidase mutations: A paradigm for neurodegeneration pathways.
Vieira SRL; Schapira AHV
Free Radic Biol Med; 2021 Nov; 175():42-55. PubMed ID: 34450264
[TBL] [Abstract][Full Text] [Related]
19. Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons.
Rocha EM; Smith GA; Park E; Cao H; Brown E; Hayes MA; Beagan J; McLean JR; Izen SC; Perez-Torres E; Hallett PJ; Isacson O
Neurobiol Dis; 2015 Oct; 82():495-503. PubMed ID: 26392287
[TBL] [Abstract][Full Text] [Related]
20. Gaucher-related synucleinopathies: the examination of sporadic neurodegeneration from a rare (disease) angle.
Sardi SP; Cheng SH; Shihabuddin LS
Prog Neurobiol; 2015 Feb; 125():47-62. PubMed ID: 25573151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
